Patents by Inventor Roberto MOTTERLINI

Roberto MOTTERLINI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Highly efficient NRF2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
    Patent number: 10519179
    Abstract: The present invention relates to highly efficient Nrf2 activators-CO-releasing molecules of formula (I) and (II) capable of increasing HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases, wherein CORM represents a carbonyl metal complex chosen from among: Mn(CO)5, formula (III), (IV), (V), (VI), (VII), (VIII) and (IX).
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 31, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Roberto Motterlini, Roberta Foresti, Anthony Ollivier, Michael Rivard, Thierry Martens
  • HIGHLY EFFICIENT NRF2 ACTIVATORS-CO-RELEASING MOLECULE HYBRIDS, THEIR USE IN THE TREATMENT OF INFLAMMATORY OR CARDIOVASCULAR DISEASES AND THEIR PROCESS OF PREPARATION
    Publication number: 20180258121
    Abstract: The present invention relates to highly efficient Nrf2 activators-CO-releasing molecules of formula (I) and (II) capable of increasing HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases, wherein CORM represents a carbonyl metal complex chosen from among: Mn(CO)5, formula (III), (IV), (V), (VI), (VII), (VIII) and (IX).
    Type: Application
    Filed: September 23, 2016
    Publication date: September 13, 2018
    Inventors: Roberto MOTTERLINI, Roberta Foresti, Anthony Ollivier, Michael Rivard, Thierry Martens
  • Fumarate-CO-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
    Patent number: 9944669
    Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: April 17, 2018
    Assignees: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Roberto Motterlini, Roberta Foresti, Thierry Martens, Michael Rivard
  • FUMARATE-CO-RELEASING MOLECULE HYBRIDS, THEIR USE IN THE TREATMENT OF INFLAMMATORY OR CARDIOVASCULAR DISEASES AND THEIR PROCESS OF PREPARATION
    Publication number: 20170174716
    Abstract: The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
    Type: Application
    Filed: March 20, 2015
    Publication date: June 22, 2017
    Applicants: UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Roberto MOTTERLINI, Roberta FORESTI, Thierry MARTENS, Michael RIVARD
  • Therapeutic delivery of carbon monoxide
    Publication number: 20070065485
    Abstract: Boranocarbonates are described for administration to a human or other mammal for delivery of carbon monoxide. The boranocarbonate is a compound or ion adapted to make CO available for physiological effect, and may be administered with a guanylate cyclase stimulant or stabilizer. The physiological effect may be stimulation of neurotransmission, vasodilation or smooth muscle relaxation.
    Type: Application
    Filed: August 4, 2004
    Publication date: March 22, 2007
    Inventors: Roberto Motterlini, Roger Alberto
  • Therapeutic delivery of carbon monoxide
    Publication number: 20060147548
    Abstract: Metal carbonyls are used in combination with at least one guanylate cyclase stimulant/stabilizer to deliver CO having biological activity, for example vasodilatation and inhibition of platelet aggregation. The two components may be administered simultaneously or sequentially. A particular described combination is tricarbonylchloro(glycinato)ruthenium(II) and the drug YC-1.
    Type: Application
    Filed: November 20, 2003
    Publication date: July 6, 2006
    Inventors: Roberto Motterlini, Brian Mann
  • Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
    Publication number: 20060127501
    Abstract: Metal carbonyls are used to deliver CO to organs to limit post-ischaemic damage. The organ may be extracorporeal, e.g. for use in a transplant, or may be an isolated organ inside or attached to the body but isolated from the blood flow. The carbonyl preferably has one or more other ligands other than CO, such as amino acids, to modulate the CO release property and solubility.
    Type: Application
    Filed: November 20, 2003
    Publication date: June 15, 2006
    Inventors: Roberto Motterlini, Brian Mann
  • THERAPEUTIC DELIVERY OF CARBON MONOXIDE
    Publication number: 20060115542
    Abstract: Metal carbonyls are used to deliver CO having biological activity, for example vasodilatation and inhibition of transplant rejection. The metal of the carbonyl is typically of groups 7 to 10, e.g. Fe and Ru. The carbonyl preferably has one or more ligands other than CO, such as amino acids, to modulate the CO release property and solubility.
    Type: Application
    Filed: January 27, 2006
    Publication date: June 1, 2006
    Inventors: Roberto MOTTERLINI, Brian Mann
  • Neuroprotective effects of polyphenolic compounds
    Publication number: 20040167217
    Abstract: The invention relates to a class of compounds, and analogs thereof, which are effective in protecting cells of the central and peripheral nervous system from deterioration and cell death arising from degenerative disease, trauma, aging or like condition, disease or disorder. The methods utilize novel anti-apoptotic and neuroprotective effects for a group of natural polyphenols in cells of the central and peripheral nervous system.
    Type: Application
    Filed: April 22, 2003
    Publication date: August 26, 2004
    Inventors: Giovanni Scapagnini, Daniel L. Alkon, Vittorio Calabrese, Roberto Motterlini, Claudia Colombrita